Skip to content

The therapeutic effect and functional neural substrate of multi-site rTMS for the treatment of major depressive disorder

The therapeutic effect and functional neural substrate of multi-site rTMS for the treatment of major depressive disorder

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049002
Enrollment
Unknown
Registered
2021-07-19
Start date
2021-08-01
Completion date
Unknown
Last updated
2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder

Interventions

Active Group One:Real TMS
Active Group Two:Real TMS

Sponsors

The Second People's Hospital of Guizhou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Inpatients (during 5 consecutive days of treatment); 2. 18-65 years old, male or female; 3. Primary DSM-V diagnosis of major depressive disorder, first course or relapse; 4. HRSD-24 score >= 21; 5. The duration of the current episode is less than one year; 6. The patient did not respond well to at least one antidepressant treatment during the course of this depressive episode (may appear before admission), or the patient was intolerant to two or more antidepressant treatment in this episode ; 7. Pass the safety screening of transcranial magnetic stimulation; 8. Ability and willingness to provide informed consent and be able to comply with the treatment plan; 9. Patients have been on stable medication (unlimited) for at least 4 weeks and are not expected to change medications during the study period.

Exclusion criteria

Exclusion criteria: 1. Severe psychotic symptoms, such as persecutory delusions, etc. during the current episode; 2. DSM-V diagnosis of substance dependence in the past 6 months (any type); 3. Concurrent, serious and unstable physical diseases, such as cardiovascular and cerebrovascular diseases; 4. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Scale;Montgomery-Asperger Depression Rating Scale;

Secondary

MeasureTime frame
Hamilton Anxiety Scale;Baker Suicide Scale;

Countries

China

Contacts

Public ContactShu Yanping

The Second People's Hospital of Guizhou

syp_8053@163.com+86 13985402340

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026